HK1132498A1 - Dihydropyrazolopyrimidinone derivative - Google Patents

Dihydropyrazolopyrimidinone derivative

Info

Publication number
HK1132498A1
HK1132498A1 HK09110110.5A HK09110110A HK1132498A1 HK 1132498 A1 HK1132498 A1 HK 1132498A1 HK 09110110 A HK09110110 A HK 09110110A HK 1132498 A1 HK1132498 A1 HK 1132498A1
Authority
HK
Hong Kong
Prior art keywords
group
lower alkyl
optionally
hydrogen atom
alkyl group
Prior art date
Application number
HK09110110.5A
Other languages
English (en)
Inventor
Toshihiro Sakamoto
Satoshi Sunami
Fuyuki Yamamoto
Kenji Niiyama
Makoto Bamba
Keiji Takahashi
Hidetomo Furuyama
Yasuhiro Goto
Takeshi Sagara
Sachie Otsuki
Toshihide Nishibata
Takashi Yoshizumi
Hiroshi Hirai
Original Assignee
Msd Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1132498(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Msd Kk filed Critical Msd Kk
Publication of HK1132498A1 publication Critical patent/HK1132498A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK09110110.5A 2006-04-27 2009-10-29 Dihydropyrazolopyrimidinone derivative HK1132498A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006124208 2006-04-27
PCT/JP2007/059416 WO2007126128A1 (ja) 2006-04-27 2007-04-25 ジヒドロピラゾロピリミジノン誘導体

Publications (1)

Publication Number Publication Date
HK1132498A1 true HK1132498A1 (en) 2010-02-26

Family

ID=38655640

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09110110.5A HK1132498A1 (en) 2006-04-27 2009-10-29 Dihydropyrazolopyrimidinone derivative

Country Status (39)

Country Link
US (4) US7834019B2 (xx)
EP (2) EP2016080B1 (xx)
JP (2) JP4513919B2 (xx)
KR (1) KR101409161B1 (xx)
CN (1) CN101432284B (xx)
AR (1) AR060635A1 (xx)
AT (1) ATE475662T1 (xx)
AU (1) AU2007244185B2 (xx)
BR (1) BRPI0710081A2 (xx)
CA (1) CA2650119C (xx)
CR (1) CR10359A (xx)
CY (2) CY1111069T1 (xx)
DE (1) DE602007008085D1 (xx)
DK (2) DK2016080T3 (xx)
DO (1) DOP2007000084A (xx)
EC (1) ECSP088812A (xx)
ES (2) ES2609087T3 (xx)
GT (1) GT200800211A (xx)
HK (1) HK1132498A1 (xx)
HN (1) HN2008001532A (xx)
HR (2) HRP20100563T1 (xx)
HU (1) HUE032987T2 (xx)
IL (1) IL194367A (xx)
LT (1) LT2017278T (xx)
MA (1) MA30428B1 (xx)
MX (1) MX2008013063A (xx)
MY (1) MY145408A (xx)
NO (1) NO341617B1 (xx)
NZ (1) NZ571196A (xx)
PE (1) PE20080695A1 (xx)
PL (2) PL2016080T3 (xx)
PT (2) PT2016080E (xx)
RU (1) RU2437885C2 (xx)
SI (2) SI2016080T1 (xx)
SV (1) SV2009003060A (xx)
TW (1) TWI409262B (xx)
UA (1) UA96152C2 (xx)
WO (2) WO2007126122A1 (xx)
ZA (1) ZA200807748B (xx)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
US8198281B2 (en) 2007-04-25 2012-06-12 Merck Sharp & Dohme Corp. Crystalline forms of dihydropyrazolopyrimidinone
WO2008141385A1 (en) * 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
AU2008315048A1 (en) * 2007-10-23 2009-04-30 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
US8507504B2 (en) 2008-06-12 2013-08-13 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
WO2010067888A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
CA2750716A1 (en) 2009-02-25 2010-09-02 Msd K.K. Pyrimidopyrimidoindazole derivative
EP2473633A4 (en) * 2009-09-02 2013-03-06 Msd Kk USE OF ONE OR MORE BIOMARKERS TO IDENTIFY A WEE1 DISEASED PATIENT AND PROCEDURE FOR TREATING CANCER MEDIATED BY DYSFUNCTIONAL OR ABERRANT P53 BY ADMINISTERING A WEE1 HEMMER
SI2477628T1 (sl) 2009-09-15 2014-11-28 Merck Sharp & Dohme Corp. Priprava oblik kristalinskega hemihidrata dihidropirazolopirimidinona
WO2012074754A1 (en) 2010-11-16 2012-06-07 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
US9207360B2 (en) * 2011-04-27 2015-12-08 Zeno Corporation Polymerizable compound, polymerizable composition, polymer, and optically anisotropic body
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
EP2776434A1 (en) 2011-10-20 2014-09-17 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CA2892361A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
AU2014251087B2 (en) 2013-04-09 2019-05-02 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
SG11201704169WA (en) * 2014-12-17 2017-07-28 Delta-Fly Pharma Inc Pharmaceutical composition for treatment or palliation of elderly or end-stage cancer patient
TW201702247A (zh) 2015-04-17 2017-01-16 艾伯維有限公司 作為ｔｎｆ信號傳遞調節劑之吲唑酮
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
TW201710257A (zh) 2015-04-17 2017-03-16 艾伯維有限公司 Ｔｎｆ信號傳遞之三環調節劑
JP6141568B1 (ja) * 2015-09-01 2017-06-07 大鵬薬品工業株式会社 新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
CA3003737C (en) * 2015-11-01 2021-09-14 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of making and using the same
CN106271589B (zh) * 2016-06-23 2018-12-28 中山市美捷时包装制品有限公司 一种用于预装阀杆、弹簧、垫片的组装设备
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
EA038128B1 (ru) 2016-09-15 2021-07-09 Бёрингер Ингельхайм Интернациональ Гмбх Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
CN106719769A (zh) * 2016-11-28 2017-05-31 山东农业大学 一种含香菇多糖、苯醚甲环唑和噻虫啉的病虫兼治农药组合物
US10954253B2 (en) 2017-01-23 2021-03-23 Shijiazhuang Sagacity New Drug Development Co., Ltd. 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
CN108623615B (zh) * 2017-03-23 2022-12-13 上海迪诺医药科技有限公司 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
JP7203816B2 (ja) * 2017-08-01 2023-01-13 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー １，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン類似体
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
US10807994B2 (en) 2017-10-09 2020-10-20 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US11299493B2 (en) 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
AU2018361010B2 (en) * 2017-11-01 2023-01-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Macrocyclic compound serving as Wee1 inhibitor and applications thereof
CN109810111B (zh) * 2017-11-20 2023-10-27 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN111315747B (zh) * 2018-01-05 2023-05-02 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
WO2019165204A1 (en) 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase
EP3758706A4 (en) * 2018-02-28 2021-11-24 The Regents Of The University Of Colorado WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THEREOF
CN117720541A (zh) * 2018-03-09 2024-03-19 里科瑞尔姆Ip控股有限责任公司 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮
CN108653282B (zh) * 2018-06-28 2020-08-14 中国科学院昆明植物研究所 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用
US20210403451A1 (en) * 2018-10-26 2021-12-30 Wenyuan Qian Pyrimidopyrazolone derivative as wee1 inhibitor and use thereof
CN113480541B (zh) * 2019-03-07 2022-09-02 湖南化工研究院有限公司 咪唑并吡啶化合物及其中间体的制备方法
KR20210141659A (ko) * 2019-03-22 2021-11-23 쇼우야오 홀딩스 (베이징) 코., 엘티디. Wee1 억제제 및 이의 제조 및 용도
CN113939296A (zh) 2019-04-09 2022-01-14 诺维逊生物股份有限公司 杂环化合物及其用途
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
FI3964510T3 (fi) 2019-04-30 2024-07-24 Wuxi Biocity Biopharmaceutics Co Ltd Wee1-inhibiittoriyhdisteen kidemuoto ja sen käyttö
EP3992193A4 (en) * 2019-06-28 2023-08-16 Shanghai Pharmaceuticals Holding Co., Ltd. PYRAZOLOPYRIMIDINE COMPOUND, METHOD OF PRODUCTION THEREOF AND APPLICATIONS THEREOF
CN112142748B (zh) 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
MX2022004934A (es) 2019-10-25 2022-05-16 Astrazeneca Ab Metodos para tratar un cancer.
CN113387962A (zh) * 2020-03-12 2021-09-14 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CN115698006B (zh) * 2020-06-17 2024-03-29 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3，4-d]嘧啶-3-酮衍生物
KR102549484B1 (ko) * 2020-12-08 2023-06-29 한국화학연구원 피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물
CN116867787A (zh) * 2021-02-09 2023-10-10 微境生物医药科技(上海)有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物
CN116848118A (zh) * 2021-02-09 2023-10-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171126A1 (zh) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
CN115197221B (zh) * 2021-04-02 2024-05-24 轩竹(北京)医药科技有限公司 二氢吡唑并嘧啶酮类大环衍生物及其用途
IL307863A (en) 2021-04-29 2023-12-01 Novartis Ag Diubiquitinase-directed chimeras and related methods
WO2022228511A1 (zh) 2021-04-30 2022-11-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物及其制备方法和用途
US20240199619A1 (en) 2021-05-28 2024-06-20 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Wee1 inhibitor and use thereof
TW202328142A (zh) * 2021-09-18 2023-07-16 香港商優領醫藥科技(香港)有限公司 含嘧啶并二氫吡唑啉酮類衍生物、其藥學上可接受的鹽及其製備方法和應用
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
CN113880844B (zh) * 2021-09-29 2023-02-14 武汉九州钰民医药科技有限公司 Wee1蛋白激酶抑制剂adavosertib的化学合成方法
WO2023072301A1 (zh) * 2021-11-01 2023-05-04 正大天晴药业集团股份有限公司 吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途
CN116462687A (zh) * 2022-01-18 2023-07-21 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184A (zh) * 2022-03-25 2023-10-03 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
CN115073460B (zh) * 2022-07-13 2023-07-25 苏州施安鼎泰生物医药技术有限公司 一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用
TW202404977A (zh) * 2022-07-15 2024-02-01 大陸商映恩生物製藥（蘇州）有限公司 一種嘧啶并五員雜環化合物、其製備方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (ja) * 1987-08-26 1997-07-09 三井製薬工業株式会社 ピリミジン類及びその薬学的に許容される塩類
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
WO1992005785A1 (en) 1990-09-28 1992-04-16 Smithkline Beecham Corporation Water soluble camptothecin analogues, processes and methods
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
DE69233739D1 (de) 1992-10-28 2008-08-07 Genentech Inc Verwendung von Antagonisten des Zellwachstumsfaktors VEGF
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
AU2003224341A1 (en) 2002-04-26 2003-11-10 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1590341B1 (en) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
EP1611125A1 (en) * 2003-02-07 2006-01-04 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en) 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
CN102827082B (zh) 2004-07-01 2015-01-07 第一三共株式会社 具有pde7抑制活性的噻吩并吡唑衍生物
AU2006205851A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer

Also Published As

Publication number Publication date
US20100063024A1 (en) 2010-03-11
DK2017278T3 (en) 2017-02-13
HRP20161763T1 (hr) 2017-02-24
TWI409262B (zh) 2013-09-21
BRPI0710081A2 (pt) 2011-08-02
RU2437885C2 (ru) 2011-12-27
UA96152C2 (xx) 2011-10-10
IL194367A (en) 2014-12-31
CN101432284A (zh) 2009-05-13
NO341617B1 (no) 2017-12-11
NO20084968L (no) 2008-11-26
DK2016080T3 (da) 2010-11-22
AU2007244185B2 (en) 2012-10-04
US20110189130A1 (en) 2011-08-04
GT200800211A (es) 2009-04-07
LT2017278T (lt) 2017-01-25
DOP2007000084A (es) 2007-12-31
JPWO2007126128A1 (ja) 2009-09-17
US7834019B2 (en) 2010-11-16
WO2007126128A1 (ja) 2007-11-08
MA30428B1 (fr) 2009-05-04
RU2008146759A (ru) 2010-06-10
PT2016080E (pt) 2010-10-14
KR20090017491A (ko) 2009-02-18
PT2017278T (pt) 2017-01-03
PE20080695A1 (es) 2008-06-28
NZ571196A (en) 2011-03-31
US8791125B2 (en) 2014-07-29
HN2008001532A (es) 2009-06-10
US20070254892A1 (en) 2007-11-01
EP2017278A1 (en) 2009-01-21
IL194367A0 (en) 2009-08-03
MX2008013063A (es) 2008-12-16
MY145408A (en) 2012-02-15
ATE475662T1 (de) 2010-08-15
EP2016080A4 (en) 2009-05-13
PL2017278T3 (pl) 2017-10-31
SI2016080T1 (sl) 2011-03-31
AU2007244185A1 (en) 2007-11-08
CA2650119A1 (en) 2007-11-08
CY1118526T1 (el) 2017-07-12
US7935708B2 (en) 2011-05-03
AR060635A1 (es) 2008-07-02
CN101432284B (zh) 2012-08-15
JP2010132689A (ja) 2010-06-17
CR10359A (es) 2009-02-19
ECSP088812A (es) 2008-11-27
JP4513919B2 (ja) 2010-07-28
CA2650119C (en) 2017-03-14
CY1111069T1 (el) 2012-05-23
HUE032987T2 (en) 2017-11-28
EP2016080B1 (en) 2010-07-28
EP2017278A4 (en) 2009-04-22
EP2016080A1 (en) 2009-01-21
WO2007126122A1 (en) 2007-11-08
EP2017278B1 (en) 2016-11-02
SI2017278T1 (sl) 2017-05-31
JP5167291B2 (ja) 2013-03-21
ES2348751T3 (es) 2010-12-13
KR101409161B1 (ko) 2014-06-19
DE602007008085D1 (en) 2010-09-09
ES2609087T3 (es) 2017-04-18
PL2016080T3 (pl) 2011-03-31
US20140303178A1 (en) 2014-10-09
TW200811176A (en) 2008-03-01
ZA200807748B (en) 2009-10-28
SV2009003060A (es) 2009-04-28
HRP20100563T1 (hr) 2010-11-30

Similar Documents

Publication Publication Date Title
HK1132498A1 (en) Dihydropyrazolopyrimidinone derivative
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
TW200833675A (en) Nicotinamide derivatives
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
WO2007140385A3 (en) Thiazole compounds as cannabinoid receptor ligands and uses thereof
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
WO2009046841A8 (de) Piperidin- und piperazinderivate zur behandlung von tumoren
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
UA89040C2 (ru) Замещенные глюкопиранозилом бензольные производные, лекарственное средство, которое содержит эти соединения
MY148538A (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
EP1740581A4 (en) PYRIDYL DERIVATIVE COMPOUNDS SUBSTITUTED AT POSITIONS 2, 4, 6 USEFUL AS INHIBITORS OF BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER'S DISEASE
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
MX339668B (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina.
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
WO2008152014A3 (en) 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
EP1817311A4 (en) 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS AS BETA SEKTRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
WO2006136837A3 (en) Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
WO2007106544A3 (en) Chelating conjugates having a substituted aromatic moiety and derivatives thereof
WO2008077885A3 (en) 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer
MX2007003872A (es) Nuevos derivados bis-azaindolicos, preparacion y su uso farmaceutico de los mismos como inhibidores de cinasas.
HK1127476A1 (en) Pyrazolopyrimidine derivative
NO20055205L (no) 4-(2-fcnylsulfanyl-fenyl)-1,2,3,6-tydropyridinderivater som serotoniniopptaksinhibitorer
MX2008001778A (es) Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
EP2100895A4 (en) TRICYCLIC COMPOUND AND ITS MEDICAL USE